Shire plc (SHPG) Misses Q3 EPS by 4c

November 1, 2016 8:18 AM EDT

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

Shire plc (NASDAQ: SHPG) reported Q3 EPS of $3.17, $0.04 worse than the analyst estimate of $3.21. Revenue for the quarter came in at $3.45 billion versus the consensus estimate of $3.57 billion.

Financial highlights

  • Very strong launch results for XIIDRA; 64,732 scripts written through October 21, with a market share of 16%.
  • Product sales growth of 110% in Q3 2016 to $3.3 billion, driven by record legacy Shire product sales and the inclusion of legacy Baxalta franchises.
  • Underlying growth in Q3 2016 hematology and immunology businesses largely in line with overall market trends; pro forma sales growth of legacy Baxalta products impacted by the timing of large orders.
  • Q3 2016 year to date growth for legacy Shire product sales was 15% (16% on a Non GAAP CER basis) and legacy Baxalta was 7% on a pro forma basis (8% on a Non GAAP CER pro forma basis), in line with our expectations.

Baxalta integration

  • Operating expense synergy initiatives ahead of schedule, including manufacturing footprint optimization review.
  • Sharp focus on transitioning legacy Baxalta products onto Shire’s commercial platform and operating execution.
  • Issued $12.1 billion aggregate principal debt at a weighted average interest rate of 2.6%; net proceeds used to fully repay bridge facility for financing Baxalta transaction.

Pipeline progress

  • Pipeline continuing to deliver with U.S. Food and Drug Administration (FDA) approval of CUVITRU, and European Commission (EC) Marketing Authorization for ONIVYDE accompanied by Orphan Drug Designation.
  • Fully enrolled Phase 3 study for SHP643 in prophylaxis of hereditary angioedema with results expected in the first half of 2017.
  • FDA resubmission of SHP465 for the treatment of ADHD on track to be made in Q4 2016.

GUIDANCE:

Shire plc sees FY2016 EPS of $12.70-$13.10, versus the consensus of $12.98. Shire plc sees FY2016 revenue of $10.8-11.0 billion, versus the consensus of $11.41 billion.

For earnings history and earnings-related data on Shire plc (SHPG) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Earnings, Guidance

Related Entities

Earnings

Add Your Comment